Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Jaguar Health (JAGX) EPS (Weighted Average and Diluted) (2016 - 2025)

Jaguar Health (JAGX) has disclosed EPS (Weighted Average and Diluted) for 9 consecutive years, with -$0.36 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 101.8% to -$0.36 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$33.6 through Dec 2025, up 65.01% year-over-year, with the annual reading at -$22.97 for FY2025, 82.42% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.36 at Jaguar Health, up from -$6.28 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $20.03 in Q4 2024, with the low at -$2545.7 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$143.5, with a median of -$8.8 recorded in 2022.
  • The sharpest move saw EPS (Weighted Average and Diluted) crashed 578663.64% in 2023, then soared 100.79% in 2024.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$87.35 in 2021, then skyrocketed by 100.5% to $0.44 in 2022, then tumbled by 578663.64% to -$2545.7 in 2023, then skyrocketed by 100.79% to $20.03 in 2024, then tumbled by 101.8% to -$0.36 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.36, -$6.28, and -$10.26 for Q4 2025, Q3 2025, and Q2 2025 respectively.